Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ACAD | Acadia Pharmaceuticals Inc

IndexRUT P/E- EPS (ttm)-0.68 Insider Own0.77% Shs Outstand163.73M Perf Week-3.31%
Market Cap3.87B Forward P/E34.65 EPS next Y0.68 Insider Trans104.80% Shs Float162.47M Perf Month-17.38%
Income-110.81M PEG- EPS next Q-0.42 Inst Own97.78% Short Float / Ratio6.27% / 6.26 Perf Quarter-2.44%
Sales550.90M P/S7.02 EPS this Y69.68% Inst Trans0.92% Short Interest10.18M Perf Half Y27.04%
Book/sh2.42 P/B9.75 EPS next Y- ROA-17.65% Target Price30.33 Perf Year41.07%
Cash/sh2.29 P/C10.31 EPS next 5Y- ROE-26.68% 52W Range13.73 - 33.99 Perf YTD48.43%
Dividend- P/FCF- EPS past 5Y10.76% ROI-24.87% 52W High-30.48% Beta0.61
Dividend %- Quick Ratio2.57 Sales past 5Y35.48% Gross Margin97.52% 52W Low72.10% ATR0.84
Employees513 Current Ratio2.62 Sales Q/Q22.79% Oper. Margin-23.14% RSI (14)31.22 Volatility3.19% 3.11%
OptionableYes Debt/Eq0.15 EPS Q/Q- Profit Margin-20.12% Rel Volume1.75 Prev Close23.29
ShortableYes LT Debt/Eq0.13 EarningsAug 02 AMC Payout- Avg Volume1.63M Price23.63
Recom2.18 SMA20-8.56% SMA50-14.96% SMA2006.46% Volume2,849,795 Change1.46%
Date Action Analyst Rating Change Price Target Change
Jan-03-23Upgrade Guggenheim Neutral → Buy $22
Nov-04-22Downgrade Goldman Neutral → Sell $15 → $12
Nov-01-22Initiated Loop Capital Hold $17
Aug-08-22Downgrade Citigroup Buy → Neutral $19 → $15
Aug-05-22Downgrade Citigroup Buy → Neutral $19 → $15
Jun-21-22Downgrade Jefferies Buy → Underperform $25 → $10
Jun-16-22Upgrade Jefferies Hold → Buy $25
Mar-16-22Upgrade Canaccord Genuity Hold → Buy $30 → $31
Feb-09-22Upgrade H.C. Wainwright Neutral → Buy $36
Jan-05-22Upgrade Citigroup Neutral → Buy $30
Sep-22-23 06:23PM
Sep-19-23 04:05PM
Aug-30-23 04:05PM
Aug-28-23 06:00PM
Aug-22-23 08:30AM
10:44AM Loading…
Aug-19-23 10:44AM
Aug-14-23 04:05PM
Aug-04-23 12:36PM
Aug-02-23 04:26PM
Aug-01-23 07:30PM
Jul-25-23 11:21AM
Jul-24-23 04:05PM
Jul-21-23 09:40AM
Jul-19-23 04:04PM
08:19AM Loading…
Jul-15-23 08:19AM
Jul-14-23 04:04PM
Jul-13-23 07:11PM
Jun-26-23 05:00PM
Jun-13-23 04:05PM
Jun-12-23 01:24PM
Jun-08-23 11:10AM
Jun-07-23 11:30AM
Jun-01-23 09:04AM
May-08-23 05:25PM
09:21AM Loading…
May-05-23 04:04PM
May-02-23 09:04AM
Apr-25-23 09:04AM
Apr-20-23 09:04AM
Apr-17-23 09:04AM
Apr-11-23 09:04AM
Mar-13-23 12:56PM
Mar-10-23 09:45PM
Mar-07-23 09:45AM
Mar-02-23 05:45AM
Mar-01-23 05:41AM
Feb-28-23 04:00PM
Feb-27-23 05:25PM
Feb-20-23 10:00AM
Feb-14-23 04:05PM
Feb-13-23 04:15PM
Jan-09-23 09:00AM
Jan-03-23 11:58AM
Dec-21-22 04:05PM
Nov-08-22 04:05PM
Nov-03-22 12:23PM
Nov-02-22 05:35PM
Nov-01-22 10:04AM
Oct-27-22 04:05PM
Oct-26-22 10:02AM
Oct-20-22 04:05PM
Oct-19-22 12:02PM
Oct-13-22 07:30AM
Oct-12-22 10:57AM
Oct-06-22 01:36PM
Oct-04-22 02:19PM
Sep-13-22 08:44AM
Sep-12-22 07:30AM
Sep-07-22 11:30AM
Sep-01-22 09:03AM
Aug-30-22 09:55AM
Aug-26-22 12:00PM
Aug-09-22 01:24PM
Aug-08-22 05:35PM
Aug-05-22 07:55AM
Aug-04-22 11:39PM
Aug-01-22 10:01AM
Jul-27-22 08:23AM
Jul-25-22 04:05PM
Jul-19-22 11:22AM
Jul-18-22 04:07PM
Jul-08-22 11:14AM
Jun-21-22 12:07PM
Jun-17-22 08:00PM
Jun-16-22 03:42PM
Jun-15-22 04:53PM
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kihara JamesPrincipal Accounting OfficerSep 15Sale25.882,00051,76010,778Sep 19 06:31 PM
Schneyer Mark C.EVP, Chief Financial OfficerAug 21Sale29.0010,000289,97015,682Aug 23 07:31 PM
DAVIS STEPHENCEOJul 14Option Exercise20.77100,0002,077,000136,695Jul 18 06:00 PM
DAVIS STEPHENCEOJul 14Sale30.04100,0003,004,35036,695Jul 18 06:00 PM
DAVIS STEPHENCEOJul 12Sale25.0555,1041,380,44936,695Jul 13 08:27 PM
DAVIS STEPHENCEOJul 11Sale25.0016,498412,45091,799Jul 13 08:27 PM
Kihara JamesPrincipal Accounting OfficerJun 15Sale24.152,00048,3009,144Jun 16 04:38 PM
Brege LauraDirectorJun 12Sale24.874,500111,90613,502Jun 14 05:14 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Option Exercise0.001,893023,798Jun 12 08:48 PM
Schneyer Mark C.EVP, Chief Financial OfficerJun 08Sale25.0297424,36922,824Jun 12 08:48 PM
BAKER BROS. ADVISORS LPDirectorMay 24Buy25.48553,26314,096,82539,317,673May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 23Option Exercise17.0125,000425,25038,620,261May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 23Buy25.41209,0535,312,45838,811,515May 24 05:09 PM
BAKER BROS. ADVISORS LPDirectorMay 22Buy24.57134,2063,297,81538,607,761May 24 05:09 PM
Schneyer Mark C.EVP, Chief Financial OfficerMay 17Sale22.5015,310344,47521,905May 19 06:48 PM
Teehan BrendanEVP, COO, Head of CommercialMay 17Sale22.5014,869334,55224,356May 19 06:43 PM
Kihara JamesPrincipal Accounting OfficerMay 17Sale22.505,947133,80811,144May 19 06:54 PM
DAVIS STEPHENCEOMay 01Sale21.187,806165,331108,297May 02 07:02 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryMay 01Sale21.1891719,42225,513May 02 07:06 PM
Teehan BrendanEVP, COO, Head of CommercialMay 01Sale21.1854811,6079,487May 02 07:04 PM
Teehan BrendanEVP, COO, Head of CommercialApr 29Option Exercise0.001,567010,035May 02 07:04 PM
DAVIS STEPHENCEOApr 29Option Exercise0.0015,6250116,103May 02 07:02 PM
Kihara JamesPrincipal Accounting OfficerApr 10Sale18.145239,4875,197Apr 11 09:15 PM
DAVIS STEPHENCEOApr 06Sale18.168,582155,849100,478Apr 07 08:34 PM
Schneyer Mark C.EVP, Chief Financial OfficerApr 06Sale18.161,91634,7957,477Apr 07 08:37 PM
Teehan BrendanEVP, COO, Head of CommercialApr 06Sale18.161,75131,7988,468Apr 07 08:44 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryApr 06Sale18.161,45626,44123,425Apr 07 08:32 PM
Kihara JamesPrincipal Accounting OfficerApr 06Sale18.1670112,7304,231Apr 07 08:41 PM
DAVIS STEPHENCEOFeb 24Sale18.783,85172,32291,727Feb 27 09:00 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryFeb 24Sale18.7880315,08020,108Feb 27 09:00 PM
Schneyer Mark C.EVP, Chief Financial OfficerFeb 24Sale18.7857710,8364,118Feb 27 09:00 PM
Teehan BrendanEVP, COO, Head of CommercialFeb 24Sale18.784618,6585,195Feb 27 09:00 PM
Kihara JamesPrincipal Accounting OfficerFeb 24Sale18.783506,5732,923Feb 27 09:00 PM
Brege LauraDirectorJan 12Option Exercise17.0112,500212,62512,500Jan 17 05:17 PM
BAKER BROS. ADVISORS LPDirectorJan 12Option Exercise5.2230,000156,60038,484,981Jan 17 04:22 PM
Brege LauraDirectorJan 12Sale18.2512,500228,1250Jan 17 05:17 PM
DAVIS STEPHENCEOJan 09Sale17.133,90466,87784,633Jan 10 08:38 PM
KIM AUSTIN D.EVP,General Counsel, SecretaryJan 09Sale17.1358910,09018,697Jan 10 08:20 PM
Teehan BrendanEVP, COO, Head of CommercialJan 09Sale17.135329,1134,549Jan 10 08:30 PM
Stankovic Srdjan R.PresidentNov 21Sale15.071,84727,83461,234Nov 22 04:34 PM
DAVIS STEPHENCEOOct 15Sale15.812,80444,33179,009Oct 18 09:16 PM
Stankovic Srdjan R.PresidentOct 15Sale15.811,32620,96456,831Oct 18 09:22 PM